Targeted tumor delivery of irinotecan through sacituzumab govitecan can help to reduce treatment-related toxicities, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.
Following initial presentation of SEASTAR trial data on the novel combination of sacituzumab govitecan plus rucaparib, which was investigated for use in metastatic triple-negative breast cancer and other advanced/metastatic solid tumors (ie, platinum-resistant ovarian cancer, urothelial cancers), at this year’s annual virtual European Society for Medical Oncology (ESMO) meeting, Timothy A. Yap, MBBS, PhD, FRCP, medical director, Institute for Applied Cancer Science, the University of Texas MD Anderson Cancer Center, discusses with The American Journal of Managed Care® the toxicities associated with this treatment and how they were managed in the investigative setting.
Transcript
How do the clinical toxicities from PARP and TOP1 inhibitors affect treatment?
Clinically, PARP inhibitors, such as rucaparib, and TOP1 inhibitors, such as irinotecan, have shown highly synergistic antitumor effects. But as noted in our ESMO presentation, clinical development of this combination has been hampered by overlapping toxicities, and these overlapping toxicities chiefly comprise myelosuppression, gastrointestinal symptoms, and fatigue. This arm of the SEASTAR study was designed to explore whether a targeted tumor delivery of the TOP1 inhibitor irinotecan through the use of sacituzumab govitecan as part of that could actually reduce the systemic toxicity of the combination. And the toxicities we observed in the study were effectively managed through dose modification and or hemopoietic growth factor support, and together with the initial encouraging signals of antitumor activity suggests that further study of this combination is warranted.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More